These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27930379)

  • 1. Reliability, Validity, and Sensitivity to Change Overtime of the Modified Melasma Area and Severity Index Score.
    Abou-Taleb DA; Ibrahim AK; Youssef EM; Moubasher AE
    Dermatol Surg; 2017 Feb; 43(2):210-217. PubMed ID: 27930379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method.
    Pandya AG; Hynan LS; Bhore R; Riley FC; Guevara IL; Grimes P; Nordlund JJ; Rendon M; Taylor S; Gottschalk RW; Agim NG; Ortonne JP
    J Am Acad Dermatol; 2011 Jan; 64(1):78-83, 83.e1-2. PubMed ID: 20398960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study of an automated method to determine Melasma Area and Severity Index.
    Tay EY; Gan EY; Tan VWD; Lin Z; Liang Y; Lin F; Wee S; Thng TG
    Br J Dermatol; 2015 Jun; 172(6):1535-1540. PubMed ID: 25641313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet-rich plasma is a useful therapeutic option in melasma.
    Hofny ERM; Abdel-Motaleb AA; Ghazally A; Ahmed AM; Hussein MRA
    J Dermatolog Treat; 2019 Jun; 30(4):396-401. PubMed ID: 30220226
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of picosecond laser for the treatment of melasma: a systematic review and meta-analysis.
    Feng J; Shen S; Song X; Xiang W
    Lasers Med Sci; 2023 Mar; 38(1):84. PubMed ID: 36897459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microdermabrasion assisted delivery of glycolic acid 70% peel for the treatment of melasma in dark-skinned patients.
    Abdel-Motaleb AA; Bakr RM
    Dermatol Ther; 2021 Jul; 34(4):e15025. PubMed ID: 34089564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative evaluation of the efficacy of intralesional tranexamic acid versus platelet rich plasma in the treatment of melasma.
    Patil NK; Bubna AK
    Dermatol Ther; 2022 Jul; 35(7):e15534. PubMed ID: 35460158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laser and laser compound therapy for melasma: a meta-analysis.
    Zhang Y; Zheng X; Chen Z; Lu L
    J Dermatolog Treat; 2020 Feb; 31(1):77-83. PubMed ID: 30702958
    [No Abstract]   [Full Text] [Related]  

  • 9. Low-power fractional CO₂ laser versus low-fluence Q-switch 1,064 nm Nd:YAG laser for treatment of melasma: a randomized, controlled, split-face study.
    Jalaly NY; Valizadeh N; Barikbin B; Yousefi M
    Am J Clin Dermatol; 2014 Aug; 15(4):357-63. PubMed ID: 24858737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proposing Melasma Severity Index: A New, More Practical, Office-based Scoring System for Assessing the Severity of Melasma.
    Majid I; Haq I; Imran S; Keen A; Aziz K; Arif T
    Indian J Dermatol; 2016; 61(1):39-44. PubMed ID: 26955093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study.
    Abd Elraouf IG; Obaid ZM; Fouda I
    Arch Dermatol Res; 2023 Aug; 315(6):1763-1770. PubMed ID: 36856856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skin hyperpigmentation index in melasma: A complementary method to classic scoring systems.
    Heidemeyer K; Cazzaniga S; Feldmeyer L; Imstepf V; Adatto M; Lehmann M; Rammlmair A; Pelloni L; Seyed Jafari SM; Bossart S
    J Cosmet Dermatol; 2023 Dec; 22(12):3405-3412. PubMed ID: 37349912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a melasma quality of life questionnaire for the Turkish language: the MelasQoL-TR study.
    Dogramaci AC; Havlucu DY; Inandi T; Balkrishnan R
    J Dermatolog Treat; 2009; 20(2):95-9. PubMed ID: 18720186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salicylic acid for the treatment of melasma: new acquisitions for monitoring the clinical improvement.
    Fabbrocini G; De Vita V; Marasca C; Palmisano F; Monfrecola G
    Skin Res Technol; 2013 Nov; 19(4):466-73. PubMed ID: 23527534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of oral tranexamic acid in melasma patients treated with IPL and low fluence QS Nd:YAG laser.
    Cho HH; Choi M; Cho S; Lee JH
    J Dermatolog Treat; 2013 Aug; 24(4):292-6. PubMed ID: 22103770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, open-label study to compare two different dosing regimens of oral tranexamic acid in treatment of moderate to severe facial melasma.
    Bhattacharjee R; Hanumanthu V; Thakur V; Bishnoi A; Vinay K; Kumar A; Parsad D; Kumaran MS
    Arch Dermatol Res; 2023 Aug; 315(6):1831-1836. PubMed ID: 36757440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet-rich plasma treatment for melasma: A pilot study.
    Sirithanabadeekul P; Dannarongchai A; Suwanchinda A
    J Cosmet Dermatol; 2020 Jun; 19(6):1321-1327. PubMed ID: 31568636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulsed dye laser versus intense pulsed light in melasma: a split-face comparative study.
    Hassan AM; Elfar NN; Rizk OM; Eissa NY
    J Dermatolog Treat; 2018 Nov; 29(7):725-732. PubMed ID: 29455565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results in low-fluence 1064-nm Q-Switched Nd:YAG laser for melasma: Is it effective?
    Gokalp H; Akkaya AD; Oram Y
    J Cosmet Dermatol; 2016 Dec; 15(4):420-426. PubMed ID: 27349828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of autologous platelet-rich-plasma versus its combination with intense pulsed light in treatment of melasma.
    Adel S; Serri A; Abd El-Raheem T
    Dermatol Ther; 2021 Jul; 34(4):e15008. PubMed ID: 34041826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.